Twist Bioscience Corp: Form 10-Q for the period ended Dec 31, 2022
Filed with the SEC on Feb 7, 2023 and accepted by EDGAR at Feb 7, 2023, 16:12 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-10-01 to 2022-12-31 | $54.2m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2022-10-01 to 2022-12-31 | $29.4m | us-gaap:CostOfRevenue |
| Research and development | 3 months2022-10-01 to 2022-12-31 | $31.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-10-01 to 2022-12-31 | $42.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-10-01 to 2022-12-31 | −$44.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-10-01 to 2022-12-31 | $1.0k | us-gaap:InterestExpense |
| Income tax | 3 months2022-10-01 to 2022-12-31 | $76.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-10-01 to 2022-12-31 | −$41.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-10-01 to 2022-12-31 | −$0.74 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-10-01 to 2022-12-31 | −$0.74 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-10-01 to 2022-12-31 | 56,444,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2022-10-01 to 2022-12-31 | −$54.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2022-10-01 to 2022-12-31 | $11.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-12-31 | $316.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $541.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $910.0m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $83.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $163.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-12-31 | $746.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-23-002560. Last ingested by Listed: Oct 27, 2026, 16:07 ET. Listed shows no prices and gives no investment advice.